Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 August 2024 | Story Valentino Ndaba | Photo Supplied
UFS Womens Day 2024 - Read More
Celebrating Women's Month at UFS: Empowering women in academia through mentorship, support, and excellence.

Improving the equity profile of the professoriate, increasing the intellectual diversity of staff, and aspiring for gender parity in all its leadership positions form an integral part of what the University of the Free State (UFS) stands for. This is also in support of Vision 130, the UFS’ bold, comprehensive strategy to renew and reimagine itself for 2034, when it will celebrate its 130th anniversary. 

Diversity and inclusivity are hallmarks of our culture and our commitment to social justice. As such, we believe there should be no limit to the career aspirations of women in academia – a belief we underscore by providing them with ample opportunities, skills development, and support to realise their ambitions, while simultaneously ensuring that they have maximum societal impact within their areas of expertise.

Passionate, talented, and innovative women have been instrumental in contributing towards excellence in teaching and learning, engaged scholarship, and research endeavours at the UFS. A prime example of this is the fact that the majority of our SARChI Research Chairs are currently being held by female researchers.

To address areas of underrepresentation of women in senior academic and leadership positions within the university, a Working Group on Gender Parity in Academic Leadership was established, with the critical mandate of driving attitudinal shifts, advocating for changes where necessary, and highlighting barriers to women's advancement. Supplementing this, we have specific and dedicated development and mentorship programmes aimed at advancing the careers of women academics.

Transformation of the Professoriate Mentoring Programme

The university’s commitment to academic excellence, impact, and transformation has transpired in a set of deliberate, comprehensive mentorship interventions to rectify gender and racial imbalances in a responsible and effective way. 

The UFS launched its Transformation of the Professoriate Mentoring Programme five years ago with the aim of developing and supporting emerging scholars on the cusp of promotion to senior academic positions. It focuses on the holistic development of the skills and attributes of emerging scholars in the core functions of teaching and learning, research, community engagement, and academic leadership in preparation for their roles as future professors and academic leaders. Currently, the overwhelming majority of participants are women.

The programme has evolved into different branches, each with a distinct focus area: 

Women Influencing Scholarship and Education (WISE)

This newly launched programme aims to nurture academic leaders while also supporting women's progression within the academic ranks. In the process, structural barriers, attitudinal issues, and behavioural impediments hindering the career progression of women in academia are addressed and overcome.

The programme is targeted at mid-career academic women, with the aim of increasing the number of women academics eligible for academic leadership and senior management positions and accelerating career progression towards professoriate levels. Among the opportunities that are unlocked are the development of personal branding, digital presence enhancement, as well as communication and presentation skills. 

Participants are also guided on emerging digital trends, and assisted in obtaining funding, project development, collaborative projects, and community building.

Women academics are encouraged to invest in themselves, and in the process, increased research productivity, impact, and visibility are achieved, and sustainable academic careers are advanced. 

Future Professoriate group

This is a tailormade development programme characterised by individual mentoring discussions with multiple mentors, quarterly group meetings, writing retreats, monthly writing spaces, and group meetings with specific discussion topics, as well as a variety of training and support activities aimed at strengthening scholarly and leadership competencies. Academics who have completed their three-year fellowship in this group proceed to serve as alumni mentors for new candidates in the programme.

• Emerging Scholar Accelerator group (ESAP)

This programme targets promising young academics in an even earlier stage of their careers, preparing them for entry into the Future Professoriate Group. Some of the activities of the two programmes are integrated to provide opportunities for colleagues from different departments and faculties to interact and benefit from the experience and competencies of the cohort. Individual career plans are drafted to monitor the progress of candidates towards different milestones, such as National Research Foundation (NRF) rating, receiving prestigious international fellowships, graduating PhD candidates, and being recognised for excellence in leadership, community engagement, and teaching and learning.

• Researcher Excellence Accelerator Programme (REAP) 

The REAP programme seeks to understand the unique needs of early career researchers and to create supportive clusters as an effective strategy to help navigate their careers through what can be a complex and daunting academic environment. Senior academics guide junior colleagues to the successful completion of their PhDs, enabling them to establish themselves as researchers with a strong research profile through access to mentors, training, peer support, and academic networks, all tailored to the specific needs of the researcher.

Positive results yielded

Half a decade of structured, intensive mentorship in the Transforming of the Professoriate Mentoring Programme has yielded positive results:

• 110 candidates have benefited from the programme over the past five years and are almost without exception performing extremely well.
• 77% of the 2023 cohort of the ESAP programme were women. 
• Success rate of the first Future Professoriate Group (measured by promotions) stands at 73%.
• Around 70% of the selected candidates in the different programmes are black South African and African foreign-born candidates, going a long way towards addressing historic imbalances in racial equity. 
• During the last four years, candidates of the programme published a total of 315 academic articles, as well as 30 books. 
• Candidates report increased international collaboration, advances in NRF ratings, and are recipients of a total of 22 prestigious research grants.
• Participants’ feedback bears evidence of not only scholarly development, but also an increased sense of engagement with the university community, and a strengthening of collaboration among junior and senior colleagues. 

Paying it forward

As candidates who have successfully completed mentorship and development programmes, in turn, become mentors to new entrants, these successes promise to grow exponentially over the coming years. The Transformation of the Professoriate Mentoring Programme aims to further strengthen its mentoring and capacity-building programmes, while simultaneously entrenching broader institutional mentoring practices to lure and retain excellent academics in all faculties and departments. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept